A woman interacts with the Homechoice Claria on her bedside table.

Homechoice Claria APD System With Sharesource 


At home or in a hospital setting: the simple choice for automated peritoneal dialysis with remote 
therapy management for adult and pediatric patients

The Homechoice Claria automated peritoneal dialysis (APD) System is built upon the market-leading Homechoice APD System. Now integrated with the Sharesource, it has user-friendly features that help end-stage renal disease patients manage their home peritoneal dialysis (PD) therapy, while keeping them remotely connected with their healthcare providers.

The Homechoice Claria APD System powered by Sharesource is also designed to improve healthcare practice efficiencies by automatically collecting and organizing data into a patient report that can be remotely accessed by healthcare providers. By reducing the manual input of patient and clinic data, healthcare practices can realize time and cost-saving efficiencies.

A man reads in bed next to the Homechoice Claris APD System

Meet Homechoice Claria APD Cycler 


Key patient-friendly features

The Homechoice Claria System is designed with the patient experience in mind, helping to support training and use.

  • Intuitive control buttons1
  • An easy-to-read, two-line OLED screen visible from multiple angles1
  • Clear on-screen instructions to guide patients through all aspects of their treatment
  • An auto-dim feature to aid sleep2
  • Availability in up to 38 languages3
  • Choice of four programs within Sharesource to meet the needs of most patients4
Woman on laptop viewing Sharesource remote patient management

Sharesource remote patient management: an integral part of the Homechoice Claria APD System

Sharesource is a secure, two-way digital platform for kidney care that allows for remote monitoring of patients. Clinicians can remotely access patient data, make informed clinical decisions and manage prescription changes.5 Homechoice Claria with Sharesource enables more patients to experience the clinical and lifestyle benefits of home dialysis.

A women in bed interacts with the Homechoice Claria

Prepare patients for automated peritoneal dialysis

To support patients' training on APD with Homechoice Claria, we offer videos on preparing and performing therapy.


My Kidney Journey

The My Kidney Journey website is an essential online resource that offers patients a variety of educational tools and resources to support making informed choices about dialysis options.

Connect with us

For more information about the Homechoice Claria APD System, connect with us.


Important Safety Information

For the safe and proper use of the products mentioned herein, please refer to the appropriate Instructions for Use or the appropriate Operator's Manual.

Intended Use

Homechoice Claria APD system is intended for automatic control of dialysis solution exchanges in the treatment of pediatric and adult renal failure patients undergoing peritoneal dialysis in the home healthcare environment including comparable use in professional healthcare facilities.

The Sharesource portal is intended for use by healthcare professionals to remotely communicate with compatible dialysis instruments and transfer data to a central database to aid in the review, analysis, and evaluation of patients’ historical treatment results. This system is not intended to be a substitute for good clinical management practices nor does its operation create decisions or treatment pathways.

 

Vantive, Homechoice, Homechoice Claria and Sharesource are trademarks of Vantive Health LLC or its affiliates.

References
  1. Vantive Health LLC. Data on file.

  2. Vantive Health LLC. Homechoice Claria APD System Patient At-Home Guide. 

  3. Vantive Health LLC. Homechoice Claria vs. HomeChoice and HomeChoice Pro Comparison Chart. 2020. 

  4. Vantive Health LLC. Sharesource Connectivity Platform User Guide. 2023.

  5. Wood E, McCarthy K, Knowles MR. Remote monitoring of peritoneal dialysis: evaluating the impact of the Claria Sharesource system. J Kidney Care. 2019;4(1).